SYRE Q1 2017 Earnings — Spyre Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

SYRESpyre Therapeutics, Inc.

$3B

Q1 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$982,000+14.3% YoY

Gross Profit

$00.0% margin

Operating Income

-$6M-644.7% margin

Net Income

-$6M-636.2% margin

EPS (Diluted)

$-11.68

QoQ Revenue Growth

-21.3%

Cash Flow

Operating Cash Flow

-$5M

Free Cash Flow

-$6M

Stock-Based Comp.

$401,000

Balance Sheet

Total Assets

$61M

Total Liabilities

$4M

Stockholders' Equity

$57M

Cash & Equivalents

$17M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$982,000	$859,000	+14.3%
Gross Profit	$0	$0	—
Operating Income	-$6M	-$5M	-38.6%
Net Income	-$6M	-$5M	-37.4%